Compare iShares Core Growth Allocation ETF (AOR) vs Baxter International Inc (BAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Baxter International Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.08, while Baxter International Inc trades at $22.08 (market cap $11.68B). The key difference: Baxter International Inc pays a 0.88% dividend while iShares Core Growth Allocation ETF pays none, and iShares Core Growth Allocation ETF is trading nearer its 52-week high, Baxter International Inc nearer its low. Which is the better fit depends on your goals.
| AOR | BAX | |
|---|---|---|
52-Week High | $69.85 | $29.22 |
52-Week Low | $61.00 | $15.80 |
Market Cap | — | $11.68B |
Sector | — | Health |
Enterprise Value | — | $19.35B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
Baxter International (BAX) trades at $22.62, up 0.71% on the day, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains challenged with negative net income margins. Recent news highlights sustainability initiatives and upcoming Q2 2026 earnings, with analyst sentiment mixed but leaning hold.
Outlook hinges on operational turnaround amid margin pressures; upside exists if cost controls and innovation boost profits, but high debt and inconsistent cash flow pose risks. The stock offers speculative value for patient investors betting on recovery, but near-term volatility is likely until earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
